Clinical Report: Utilization of Patient-Derived Organotypic Tumor Spheroids in HCC
Overview
This report discusses the use of a patient-derived organotypic tumor spheroid (PDOTS) model to predict treatment response in advanced hepatocellular carcinoma (HCC). A case study demonstrated that the PDOTS model successfully identified a sensitive combination therapy, leading to a significant clinical response in the patient.
Background
Advanced hepatocellular carcinoma (HCC) poses a significant challenge in treatment due to its poor prognosis and the limitations of current predictive models for immunotherapy response. Traditional models often fail to accurately simulate the tumor immune microenvironment, necessitating the development of more effective tools for personalized therapy. The PDOTS model represents a promising advancement in this area, potentially guiding treatment decisions based on individual tumor characteristics.
Data Highlights
The PDOTS model indicated a 50% Organoid Killing Index for the combination of Lenvatinib and Tislelizumab, which was not observed with either agent alone.
Key Findings
The PDOTS model can preserve the tumor immune microenvironment, enhancing predictive accuracy for treatment response.
In the case study, the patient exhibited a partial response after 6 cycles of the identified combination therapy.
Serum biomarkers (AFP, PIVKA-II) normalized following treatment, indicating a significant clinical response.
The results suggest that PDOTS may be a valuable tool for guiding personalized immunotherapy in advanced HCC.
Further validation in larger cohorts is necessary to confirm the predictive value of the PDOTS model.
Clinical Implications
The PDOTS model may serve as a novel platform for predicting treatment responses in advanced HCC, potentially improving personalized therapy strategies. Clinicians should consider integrating such models into their treatment planning to enhance outcomes for patients with advanced disease.
Conclusion
This case study provides preliminary evidence supporting the utility of the PDOTS model in guiding immunotherapy decisions for advanced HCC. Further research is essential to validate these findings in broader patient populations.
